MTOR and ovarian carcinoma: The novel Gab2/PI3K/Zeb1 pathway can be targeted by PI3K and mammalian target of rapamycin (mTOR) inhibitors and can be potentially used to treat Gab2-driven ovarian cancer in combination with standard chemotherapy.